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LAY ABSTRACT
For children with spastic cerebral palsy who are able 
to walk independently, botulinum toxin injections are 
often part of a combined treatment to improve their 
functioning. Although it is known from the scientific li-
terature that such combinations are more effective than 
low-intensity standard care, the relative contribution of 
the costly botulinum toxin injections to the total treat-
ment effect is unknown. The aim of this study was to 
determine the added value of providing botulinum toxin 
treatment prior to a period of comprehensive rehabilita-
tion compared with comprehensive rehabilitation alone 
in a group of 65 children aged 4–12 years. The effect 
outcomes measured were: leg muscle strength, muscle 
length and spasticity of several leg muscles, CP-related 
pain, walking speed, several gait pattern parameters, 
the degree to which individual therapy goals were at-
tained, and parent-reported general functioning. At the 
group level, no differences were found in effect between 
the group that received botulinum toxin injections and 
comprehensive rehabilitation, and the group that recei-
ved comprehensive rehabilitation alone. This suggests 
that the widespread prescription and use of botulinum 
toxin for spastic cerebral palsy in this age- and severity-
subgroup needs critical reconsideration.
Objective: Botulinum toxin (BoNT-A) is widely used 
in combined treatment for spastic cerebral palsy, but 
its added value preceding comprehensive rehabilita-
tion for motor impairments, gait, and goal attainment 
has not been studied. 
Design: A comparative multi-centre trial, in which 
two groups underwent comprehensive rehabilitation 
(i.e. high-intensive functional physiotherapy, and 
indicated casting/orthoses). One group received in-
tramuscular BoNT-A prior to rehabilitation, and the 
other group did not receive BoNT-A. 
Subjects/patients: Children with spastic cerebral 
palsy, Gross Motor Function Classification System 
(GMFCS) levels I–III, age range 4–12 years, indi-
cated for BoNT-A treatment regarding mobility pro-
blems. 
Methods: Sixty-five children participated (37 boys), 
mean age 7.3 years (standard deviation (SD) 2.3, 
range 4–12 years), equally distributed across GMFCS 
levels. Forty-one children received BoNT-A+ com-
prehensive rehabilitation and 24 received compre-
hensive rehabilitation only. Functional leg muscle 
strength, passive range of motion, angle of catch, ce-
rebral palsy-related pain, walking speed, kinematic 
gait parameters, goal attainment, and proxy-repor-
ted general functioning were assessed at baseline, 
primary end-point (12 weeks) and 24-week follow-up. 
Statistical analyses were performed with linear mixed 
models. 
Results: At the primary end-point there were no sta-
tistically significant differences in treatment effects 
between the groups, except for the angle-of-catch 
of the rectus femoris, which was in favour of com-
prehensive rehabilitation without BoNT-A (12° dif-
ference, 95% confidence interval (95% CI) 2:23, 
p = 0.025). Results at follow-up were similar.
Conclusion: At the group level, treating with BoNT-
A prior to comprehensive rehabilitation did not add 
to the clinical effectiveness of rehabilitation. Thus, 
BoNT-A prescription and use should be critically re-
considered in this cerebral palsy age- and GMFCS-
subgroup.
Key words: spastic cerebral palsy; botulinum toxin; functio-
nal physiotherapy; casting; orthoses; impairments; goal at-
tainment; paediatric rehabilitation.
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Botulinum toxin (BoNT-A) has been widely used in the treatment of ambulatory children with spastic 
cerebral palsy (CP) since the 1990s (1, 2). BoNT-A 
injections in the leg muscles temporarily block the 
neuromuscular junctions and thereby provide (better) 
conditions to optimize and reinforce the effects of post-
BoNT-A adjunctive interventions. However, there is a 
consensus that BoNT-A should never be a stand-alone 
intervention (3–8). Therefore, BoNT-A injections are 
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733BoNT-A in rehabilitation for childhood spastic CP
(52). Because it is unclear whether (absent) impro-
vements in a single category from the International 
Classification of Functioning Disability and Health/ 
International Classification of Functioning Disability 
and Health-Children and Youth (ICF/ICF-CY) fram-
ework (53, 54) are related to (absent) improvements in 
other ICF categories (9, 55), the aim of this study was 
to determine the added value of BoNT-A preceding a 
period of CR for ambulatory children with spastic CP 
for a broad range of effect outcomes across ICF cate-
gories. This study evaluated CP-related pain, functional 
leg muscle strength, passive range of motion, angle of 
catch, walking speed and kinematic gait parameters, 
as well as proxy-reported general functioning and at-
tainment of individual activity-related therapy goals. 
METHODS
Study design, participants and enrolment
The study design, inclusion criteria and procedures have been 
described previously (52). This methods section provides only 
summary data.
A single-blind, partly-randomized, comparative multi-centre 
trial was performed, in which the effectiveness of BoNT-A 
plus a 12-week period of comprehensive rehabilitation CR 
(BoNT-A+CR) was compared with the effectiveness of a 
12-week period of CR alone (only-CR). Two groups received 
CR, consisting of individually tailored, high-intensity, goal-
directed physiotherapy (iPT), and, if necessary, serial casting 
and/or AFOs. One of the groups received BoNT-A injections 
prior to CR, and the other group did not receive any BoNT-A. 
Participants were randomized to 1 of 2 groups, except when 
objections to randomization were so strong that families refused 
to participate. These families were offered participation in the 
treatment group they preferred. Power calculations were per-
formed for the primary outcome measure gross motor function. 
The total sample size of 65 children was considered sufficient 
for the effect outcomes presented here, especially since both legs 
were taken into account in the analysis of bilaterally measured 
outcomes (if spastic). 
During regular spasticity-management team consultations 
in 2 Dutch university hospitals and 5 rehabilitation centres, 
experienced multidisciplinary teams of professionals assessed 
children for eligibility. The main inclusion criteria were: unila-
teral or bilateral spastic CP in the leg(s), classified at levels I–III 
of the Gross Motor Function Classification System (GMFCS), 
age range 4–12 years, with an indication for multi-level BoNT-A 
treatment for mobility problems. 
Written informed consent was obtained for all participating 
children. The ethics committee of Erasmus MC approved the 
SPACE BOP study, and the trial was registered in the Dutch 
Trial Register (NTR TC1655).
Randomization and blinding
In case of randomized participation, children were centrally 
assigned to 1 of the 2 intervention groups and allocation was 
concealed until after baseline measurements. We attempted to 
mask the outcome assessors, the children’s physiotherapists, 
and those administering casting and AFO to whether or not 
BoNT-A was injected. After anonymization and coding, data 
generally given as part of a combined, multimodal 
treatment package. 
Although the body of evidence for such combined 
treatment packages including BoNT-A has increased 
since the first systematic review (3), the evidence is 
ambiguous (9) and even conflicting (10). Since it is dif-
ficult to perform controlled intervention studies in CP 
(5, 11), discussion about the content and contribution 
of both BoNT-A treatment and the adjunctive post-
BoNT-A treatment modalities is ongoing (7, 11–24). 
However, previous controlled trials have shown that 
a more comprehensive treatment package including 
non-pharmacological interventions (such as functional 
and goal-directed physiotherapy, serial casting and/
or ankle-foot orthoses (AFO)) following BoNT-A 
injections generally leads to better results than regular 
low-intensity “maintenance care” (e.g. 4, 11, 25–33).
An important characteristic of previous BoNT-A 
research is that the (adjunctive) non-pharmacological 
interventions are, in general, poorly described, with 
unknown content and of unknown quality (13, 16, 
34–36). In 2006, Scholtes and colleagues noted that it 
was unclear to what degree positive effects of combi-
ned BoNT-A and comprehensive rehabilitation (CR) 
(compared with standard low-intensive care) could 
be attributed to BoNT-A injections or to characteris-
tics of the other modalities applied in the ambulatory 
subgroup of children with CP (33). This “black box” 
issue has been reported frequently (11, 16, 34, 35, 37, 
38). In recent years, there has also been increasing 
support for intensive individually tailored, functional 
and goal-directed physiotherapy-based interventions 
for spastic CP (in comparison with effectiveness of 
standard low-intensity care) (13, 39–51).
The added value of BoNT-A prior to CR (consisting 
of non-pharmacological modalities; physiotherapy, 
casting and orthosis) has not previously been explicitly 
studied, although there are a number of disadvantages 
to BoNT-A treatment (e.g. burden of treatment, toxin, 
use of anaesthetics, repeated treatments, expense). 
Therefore, we performed a clinical trial including 
economic evaluation named SPACE BOP (SPAstic 
cerebral palsy; Cost-Effectiveness of BOtulinum toxin 
and Physiotherapy). In this trial, the effectiveness and 
costs of BoNT-A plus CR were compared with the ef-
fectiveness and costs of CR alone in a group of ambu-
latory children with spastic CP in the age range 4–12 
years. Both intervention groups received an equally 
high-intensity, best-available-evidence-based package 
of non-pharmacological interventions; physiotherapy, 
casting and orthosis. Improvement was found at the 
group level in both groups with regard to gross motor 
function, everyday physical activity levels and HRQoL, 
but there were no differences in effect between groups 
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734 F. Schasfoort et al.
analyses were performed by individuals not involved in the 
interventions or outcome assessments. 
Procedures
To enable a fair comparison of both costs (see (52)) and ef-
fects between the 2 intervention groups, BoNT-A treatment 
plans were made for each child. The need for serial casting and 
prescription or (re)alignment of AFOs was also determined. In 
the group that received BoNT-A injections, these were admi-
nistered under general anaesthesia by experienced clinicians 
in a paediatric hospital day-care setting. Clinicians adhered to 
recommendations about preparations, cautions, dose modifiers, 
localization techniques, and safety aspects, as described in the 
European Consensus 2009 (5). In all cases, preparations of botu-
linum toxin serotype A – Botox® (Allergan Inc., Eindhoven, The 
Netherlands) were used, and age- and weight-related maximum 
allowed doses were injected. Post-injection side-effects and/or 
adverse events were monitored. The CR period, during which 
all children had iPT, started one week after BoNT-A injections. 
An iPT guideline was developed. based on best-available 
evidence in 2010 (46, 56). During a 12-week period, the 
children ideally had 3 45–60 min physiotherapy sessions each 
week, with at least 1 rest day between sessions. Sessions were 
individually scheduled at the children’s special schools and/
or in private practices. Because of large heterogeneity that is 
inherent to CP, the content of each session was individually 
tailored within the framework of the guideline, and strongly 
relied on physiotherapists’ clinical reasoning abilities. After a 
dynamic and playful warm-up, the main therapy components 
consisted of functional strength exercises and functional 
goal-directed activity-focused exercises. Progressive resistance 
exercises (PRE) were done to improve strength, based on 
current guidelines for typically developing children (46), and 
children with CP (i.e. intensity of 8–15 repetition maximum 
(RM)) (56). Functional goal-directed exercises were focused 
at the ICF activity/mobility categories, and were based on the 
families’ request for help. Range of motion exercises were not 
included in therapy sessions except for some time to explain the 
”homework” (50). All involved therapists were specialized in 
paediatric physiotherapy. Information about therapy compliance 
and content of each session was obtained from the therapists’ 
administrations and custom-made iPT diaries. After primary 
end-point measurements, the physiotherapy returned to the 
children’s individual pre-study intensity. 
In both intervention groups, 2–4 weeks of serial casting (i.e. 
weekly changed below-knee walking casts), starting about 1 
week after the iPT period commenced, could be prescribed in 
cases in which passive ankle dorsiflexion with extended knee 
was less than 0°. The iPT sessions continued when children 
wore casts. If necessary, alignment of current or new AFOs was 
also arranged. Primary end-point measurements were perfor-
med when the 12-week iPT period had ended, and follow-up 
measurements were performed 12 weeks thereafter. 
Outcome measures
Intensity of current CP-related pain was reported by the children 
using a paediatric visual analogue scale (VAS) with emoticon 
faces (5-point scale). 
Functional leg muscle strength was measured with a Sit-to-
Stand (STS) test (57), in which the child had to attain a standing 
position, without using the arms and with no assistance. The 
starting position is on a small bench, seated with feet flat on the 
floor and knees flexed at 90°. The maximum number of repeti-
tions in which the legs and hips were within 15° of the extended 
position within 30 s was counted. This STS test is valid and has 
been used before in effectiveness research (43, 49).
The guideline ”standard physical examination of children with 
central motor paresis” (58) was used to determine the passive 
range of motion (passive ROM) and angle of catch (AoC). A 
Lafayette goniometer was used to measure the passive ROM 
(in absolute degrees) during slow passive stretch as an indica-
tor of muscle length. This was done for 8 outcome measures: 
hip adduction, hip abduction in flexion, hip extension while 
prone, knee extension, the popliteal angle of the knee, knee 
flexion while prone, ankle dorsiflexion with knee flexed 90°, 
and ankle dorsiflexion with an extended knee, for both legs in 
case of bilateral CP. 
As an indicator of spasticity, it was assessed whether there 
was a catch (i.e. a sudden increase in muscle tone, considerably 
blocking further movement) during fast passive stretch, for both 
legs separately in case of bilateral CP. The AoC was noted for 
fast passive stretches: hip abduction in flexion (AoC adductor 
muscles), the popliteal angle (AoC hamstring muscles), knee 
flexion while prone (AoC rectus femoris muscle), ankle dorsi-
flexion with knee in 90° flexion (AoC soleus muscle), and ankle 
dorsiflexion with extended knee (AoC gastrocnemii muscles). 
These 5 AoC outcome measures were expressed as the number 
of degrees short of a physiologically normal end of range for 
their corresponding passive ROM (i.e. the greater the deficit, 
the worse the spasticity). The number of degrees short was 0° 
if there was no catch present. 
Walking speed and kinematic gait parameters were deter-
mined from 2-dimensional instrumented gait analysis, for 
both legs in case of bilateral spastic CP. This was done while 
walking barefoot and with footwear/AFO on a 10-m walkway, 
while children were instructed to walk at a comfortable walking 
speed. Two digital cameras were used to capture sagittal and 
dorsal views. Passive markers were attached to relevant bony 
markers, and the locations of the markers were digitalized and 
transformed. Walking speed and 2D kinematics were determi-
ned from the 2D space calibrated middle 3 m of the walk-way. 
Walking speed was calculated from the sagittal spatiotemporal 
information of the lateral malleolus. 
From the sagittal position of the markers, 4 effect outcomes 
were determined: the inter-segmental joint angle of the ankle 
during mid-stance and during mid-swing, the knee angle during 
mid-stance and the maximum knee angle during the swing phase 
(i.e. absolute joint angle). 
For each kinematic gait parameter, the deviation (in °) from 
a physiologically normal joint-angle-range (59) was also cal-
culated. If the absolute angle was within a certain pre-defined 
bandwidth, it was considered as non-deviant. In our opinion, 
this better reflects improvements at the group level because a 
shift within a physiologically normal bandwidth range should 
not be considered as improvement. Moreover, it better adjusts 
for the different pathological walking types (60). 
The satisfaction of primary caregivers regarding functioning 
of their child in general was assessed with a VAS with scores 
ranging from 0 (very dissatisfied) to 10 (very satisfied). Using 
a second VAS with the same scoring range from 0 to 10, the 
child’s satisfaction with its own functioning was proxy-assessed. 
Finally, goal attainment scaling (GAS) was used as an effect 
outcome. GAS is increasingly used in studies of BoNT-A treat-
ment for CP (61–64), because its responsiveness is assumed to 
be better than that of more generic measures (7, 65–67). GAS 
measures the extent to which individual therapy goals are at-
tained on a 6-point scale (–3 = deterioration; –2 = baseline score; 
–1 = improved but less than goal; 0=goal attained; +1 = more 
www.medicaljournals.se/jrm
JR
M
JR
M
Jo
ur
na
l o
f 
R
eh
ab
ili
ta
ti
on
 M
ed
ic
in
e
JR
M
Jo
ur
na
l o
f 
R
eh
ab
ili
ta
ti
on
 M
ed
ic
in
e
735BoNT-A in rehabilitation for childhood spastic CP
than goal attained; +2 = far more than goal attained). For each 
child, an individual ”SMART” goal (i.e. specific, measurable, 
acceptable, relevant and time-related goals) in the ICF activity 
category was set before treatment started for the treatment period 
up to the primary end-point at 12 weeks. The GAS scales were 
set in dialogue between families and physiotherapist, based on 
the request for help as discussed in the spasticity management 
consultation, and were scored by the child’s therapist at 12 and 
24 weeks (with additional video check by an independent as-
sessor not involved in any treatment modality). 
Statistical analyses
First, baseline characteristics of participating children and the 
different treatment modalities they received in the 2 interven-
tion groups were described and compared using conservative 
non-parametric tests. Subsequently, baseline comparability 
regarding the effect outcomes was checked in the same way. 
The comparative effectiveness analyses compared treatment 
outcomes of BoNT-A+CR with the outcomes of only-CR to es-
timate differences in effect. For the randomized participants this 
was done according to the intention-to-treat (ITT) principle. Two 
separate analyses were performed to compare baseline scores 
with the scores at 12 weeks (primary end-point) and with scores 
at 24 weeks (follow-up), using linear mixed model analyses. 
We adjusted for the dependency of repeated observations in 
each subject with a random intercept, and also adjusted for the 
number of previous BoNT-A treatments, age and GMFCS level. 
For the bilaterally measured outcome measures, in principle, 
both legs were included in the analyses for children with bilateral 
spastic CP (with an additional left/right adjustment). For muscle 
length, spasticity and gait, however, a leg was included in the 
mixed models analyses only when the child’s BoNT-A treatment 
plan targeted muscles or muscle groups that were expected to 
have an effect on that particular effect outcome. For example, 
if a child’s BoNT-A treatment plan targeted the gastrocnemius 
muscles, the leg was included only in the mixed models for the 
passive ROM effect outcomes knee extension, popliteal angle of 
the knee, knee flexion while prone, ankle dorsiflexion with knee 
flexed 90°, and ankle dorsiflexion with an extended knee, the 
effect outcome AoC for ankle dorsiflexion with extended knee, 
and all kinematic gait parameters. This grouping of ”targeted 
muscle/effect outcome – combinations” was based on expert 
opinion injection schemes. 
Finally, because our study was not fully randomized and 
we also allowed participation in the treatment group that was 
strongly preferred by families, we adjusted for the strength of 
the preference. All statistical analyses were carried out using 
IBM-SPSS statistics 21, and p ≤ 0.05 was considered statistically 
significant, with no adjustment for multiple comparisons. 
RESULTS
A total of 757 children were assessed for study eligibility 
between October 2009 and September 2013. Of these, 
634 did not meet the inclusion criteria regarding their 
GMFCS level or age (see figure in Schasfoort et al. 2017 
(52)). Of 123 families who were asked to participate, 65 
had their child enrolled in our partly randomized study. 
For various reasons, 60% of the participants had such 
a strong preference for one of the two interventions 
that they had serious objections towards randomiza-
tion. Only 10 families (15%) were completely neutral 
towards receiving one or the other intervention. 
There were 37 boys and 28 girls, with a mean age 
of 7 years and 4 months (standard deviation (SD) 2 
years, 4 months, age range 4–12 years). Fourteen par-
ticipants had unilateral spastic CP subtype and 51 had 
the bilateral subtype; and 19, 23 and 23 children were 
classified as GMFCS levels I, II and III, respectively. 
There were no drop-outs and few missing data (see 
right-hand columns in Tables III and IV). 
After the baseline measurements, 41 children recei-
ved BoNT-A+CR and 24 children started a 12-week 
period of CR alone. Except for a significantly higher 
number of previous BoNT-A treatments in the BoNT-
A+CR group (p = 0.002), there were no significant dif-
ferences between the 2 intervention groups regarding 
patient characteristics (Table I). 
Children were evenly distributed over GMFCS 
levels between groups. For the children who received 
BoNT-A, the mean dose of intramuscular BoNT-A was 
9 (SD 5), 17 (SD 5) and 17 (SD 4) units per kg body-
weight for GMFCS levels I, II and III, respectively. 
Except for the rectus femoris muscle (p = 0.003), there 
were no significant differences between the interven-
tion groups regarding the particular muscles that were 
targeted in the children’s prescribed BoNT-A treatment 
plans or the characteristics of the other treatment mo-
dalities (Table II).
Comparison of baseline scores for effect outcomes 
in the 2 intervention groups showed that the interven-
tion groups were comparable, except for passive ROM 
for ankle dorsiflexion with an extended knee and the 
AoCs of the adductor and hamstring muscles (Tables 
III and IV). 
Within both intervention groups, in general, changes 
over time for the different effect outcomes were in the 
same direction and of equal size between baseline and 
primary end-point (i.e. 12 weeks after the start of CR) 
(Table III). This was also the case for changes between 
baseline and follow-up (i.e. after 24 weeks; Table IV). 
The comparative effectiveness analyses showed that the-
re were no statistically significant differences in treatment 
effect between the 2 groups at primary end-point (Table 
III), except for the AoC of the m rectus femoris, which 
was a clinically relevant difference in effect in favour 
of the only-CR group (12° difference between groups, 
p = 0.025). At follow-up, the kinematic gait parameter 
maximum knee angle during the swing phase while 
walking barefoot was the only effect outcome that 
showed a statistically significant and clinically relevant 
difference in effect in favour of the BoNT-A+CR group 
(6° difference between groups in favour of BoNT-
A+CR, p = 0.034). However, this difference in effect 
was not significant with gait parameters expressed as 
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Table I. Characteristics of the participants in the 2 intervention groups 
Baseline characteristics of participants 
BoNT-A+CR
n = 41 children
n = 75 spastic legs
CR-only
n = 24 children
n = 41 spastic legs p-value
GMFCS level: I/II/III, % 29/32/39 29/42/29 0.656
CP type: unilateral/bilateral, % 17/83 29/71 0.258
Age, years and months, mean (SD) 7 y 6 m (2 y 5 m) 6 y 11 m (2 y 4 m) 0.324
Sex: boys/girls, % 54/46 62/38 0.486
Body weight (kg), mean (SD) 25.0 (9.4) 24.3 (9.6) 0.619
Length (m) mean (SD) 1.22 (0.14) 1.18 (0.15) 0.292
  Growth between baseline and 12 weeksa 0.02 (0.02) 0.02 (0.01) 0.726
  Growth between baseline and 24 weeksa 0.04 (0,03) 0.04 (0.02) 0.992
BMI, mean (SD) 16.3 (2.5) 16.7 (2.2) 0.345
Number of weeks of gestation, mean (SD) 33 (5) 34 (4) 0.554
Regular school/special school, % 49/51 46/54 0.818
Assistive devices, %
  Does not use assistive devices 2 4
  Uses orthopaedic shoes and/or AFO 39 42 0.888
  Uses multiple devices, including (wheeled) walker, wheelchair 59 54
Walking pattern type (Amsterdam Gait Classificationb), %
  Barefoot, distribution across types 1–5 1/4/31/51/13 2/0/32/59/7 0.875
  With footwear/AFO, distribution across types 1–5 4/13/19/60/4 3/5/13/72/8 0.082
Number of previous BoNT-A treatment 0/1/≥ 2, % 20/34/46 62/17/21 0.002*
Reported unpleasant experiences previous BoNT-A treatment, % 30 56 0.168
*p ≤ 0.05. 
aNote that there were no differences in growth between the botulinum toxin (BoNT-A)+ comprehensive rehabilitation (CR) group and the CR-only group. 
bBased on the Amsterdam Gait Classification (60), which distinguishes 5 different pathological gait types for spastic cerebral palsy (CP) due to muscle weakness 
and/or shortening and muscle activation problems (timing, hyperactivity). Spastic legs are classified according to the position of the knee (hyperflexion, normal 
or hyperextension) and foot contact (full contact or incomplete) during mid-stance during the gait cycle: type 1= knee position is normal but full foot contact 
(insufficient muscles causing problems in the swing phase), type 2 = hyperextension knee plus full contact, type 3= hyperextension knee plus incomplete contact, 
type 4 = hyperflexion knee plus incomplete contact, type 5 = hyperflexion knee plus full contact. 
GMFCS: Gross Motor Function Classification System; SD: standard deviation; AFO: ankle-foot orthoses; BMI: body mass index.
Table II. Characteristics of different treatment components in the 2 intervention groups
Characteristics of individual treatment modalities
BoNT-A+CR  
n = 41 children
n =75 spastic legs
CR-only 
n =24 children
n =41 spastic legs p-value
Prescribed number of BoNT-A units/kg bodyweight, mean (SD)a 15 (6) 13 (6) 0.110
Legs in which particular hypertonic muscle was targeted, n (%)
   m psoasa 25 (33) 11 (27) 0.533
   mm adductorsa 20 (27) 6 (15) 0.167
   m gracilisa 57 (76) 26 (63) 0.197
   m semimembranosusa 59 (79) 29 (71) 0.340
   m semitendinosusa 60 (80) 29 (71) 0.262
   m rectus femorisa 21 (28) 2 (5) 0.003*
   m gastrocnemius medialisa 52 (69) 22 (54) 0.109
   m gastrocnemius lateralisa 36 (48) 19 (46) 0.998
   m soleusa 11 (15) 4 (10) 0.569
   m tibialis posteriora 8 (11) 6 (15) 0.560
   other lower leg musclesa 7 (9) 1 (3) 0.257
Casting period prescribed for child (uni- or bi-lateral), % 59 33 0.072
  Duration of casting period in weeks when prescribed, mean (SD) 3.0 (2.0) 3.0 (1.6) 0.782
  Children with problem(s) with cast(s) during iPT period, % 29 38 0.663
New AFO(s) prescribed or realignment current AFO(s), % 34 29 0.677
  Children with problem(s) with AFO(s) during iPT period, % 43 43 1.000
Sessions during the 12-week iPT period, mean (SD)b 31 (6) 31 (4) 0.989
Cost-declared PT min baseline – 12 weeks, mean (SD)b 1,668 (661) 1,536 (661) 0.903
  Mean number of effective iPT min (i.e. spent with functional strength training & activity exercises 
according to iPT guideline), relative to cost-declared PT min between baseline - 12 weeks (%)c 1,290 (77) 1,196 (78)
  Number of weeks with minimum of 3 sessions during iPT period, mean (SD)c 8 (3) 8 (2)
  Sessions during the 12-week iPT period with a rest day following a session spent with functional 
strength training, mean (SD)c 23 (5) 23 (5)
Cost-declared PT min between – 12 and 24 weeks, mean (SD)b 700 (393) 558 (236) 0.151
*p ≤ 0.05. 
aChildren in the ”CR-only” treatment group did not receive botulinum toxin (BoNT-A), but treatment plans were made for all children to determine comparability 
of treatment groups as well as costs for an economic evaluation which was also part of our study, bbased on PT business administrations of all 65 participants, 
cbased on custom made iPT period therapy diaries of n = 64 participants as filled in by their PT.
CR: comprehensive rehabilitation; SD: standard deviation; AFO: ankle-foot orthoses; iPT; intensive physiotherapy; PT: physical therapy/therapist; min: minutes.
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the deviation in degrees from a physiologically normal 
gait range (1° difference between groups in favour of 
BoNT-A+CR, p = 0.510) (Table IV). 
Goal attainment scaling showed similar patterns 
for both intervention groups (Fig. 1). There were no 
differences in effect between interventions at primary 
end-point (0.1estimated difference in favour of only-
CR, 95% CI –0.71–0.93, p = 0.791) or at follow-up 
(0.2 difference in favour of BoNT-A+CR, 95% CI 
–1.13–0.75, p = 0.688). 
There were no serious side-effects and/or adverse 
events related to BoNT-A and/or CR, but the casting 
periods and/or alignment of AFOs was complicated in 
a number of cases in both groups, mainly due to pain 
or pressure complaints (Table I). 
DISCUSSION
In the SPACE BOP study, the added value of BoNT-A 
treatment preceding a period of comprehensive reha-
bilitation (CR) was determined in an ambulatory group 
of 65 children with spastic CP in the age range 4–12 
years, who were equally distributed across GMFCS le-
vels I–III. Differences in treatment effects (and costs, as 
described previously (52)) were studied between a group 
of 41 children receiving BoNT-A+CR and a group of 
24 children receiving only-CR. One full treatment cycle 
per child was followed, with a large number of outcome 
measures across ICF categories: pain, muscle strength 
and length, spasticity, walking speed, gait characteris-
tics, proxy-reported overall functioning, individual goal 
attainment, gross motor function, everyday physical 
activity levels, and health-related quality of life. 
For the effect outcomes, gross motor function, every-
day physical activity levels and health-related quality of 
life, it was found previously that treatment regimes with 
and without BoNT-A were approximately equally effec-
tive (52). For the presently described effect outcomes 
pain, muscle strength and length, spasticity, walking 
speed, gait characteristics, proxy-reported overall fun-
ctioning and individual goal attainment, the findings 
at primary end-point in the BoNT-A+CR group were 
largely in accordance with previously reported findings 
(11, 32, 33, 68–71). However, similar results were found 
in the smaller intervention group that received only CR. 
Treatment regimes with and without BoNT-A appeared 
to be equally effective at the group level. Findings at 
24-week follow-up also showed no difference in ef-
fectiveness between groups. Thus, at the group level, 
no evidence was found for the added value of BoNT-A 
injections when preceding CR for ambulatory children 
with spastic CP in the age range 4–12 years. 
These results may appear to contradict previous 
findings, but this is not the case. When the literature 
is critically appraised, there are some indications that 
the relative contribution of factors other than BoNT-A 
to overall effectiveness of combined treatment packa-
ges may have been underestimated. For example, in 
the uncontrolled observational study by Molenaers 
et al. (14) in a very large group of children with CP 
(n = 577), all children received BoNT-A injections 
plus physiotherapy, plus additional casting and/or 
AFOs. Results showed that increased intensity of 
physiotherapy, post-injection casting and increased 
use of orthoses significantly contributed to better out-
come (all p ≤ 0.005), whereas the correlation between 
total BoNT-A dosage and goal attainment was not 
significant (14). In a randomized cross-over trial by 
Reddihough and colleagues, the physiotherapy period 
intensity during the more effective BoNT-A phase and 
the less-effective control phase differed (mean 28 vs 
21 h) (69), indicating that intensity of PT may also 
be an important determinant of effectiveness. It has 
also been reported that larger parental satisfaction 
in the BoNT-A intervention group was not related to 
improvements (thereby suggesting a possible placebo 
effect), and that improvement lasted longer than the 
pharmacological effect (4). In the 2010 international 
consensus statement it was acknowledged that the ef-
fects of serial casting seemed to be at least as strong, 
and in some studies even stronger, than the effects of 
BoNT-A (6). In another uncontrolled small study by 
Yap et al., it was found that child, family, and treatment 
characteristics influence the degree of responsiveness 
to BoNT-A treatment (plus post-BoNT interventions), 
and that the contribution of contextual factors may be 
underappreciated (72). 
In short, a stronger relative contribution of factors 
other than BoNT-A may equally well explain im-
provements, especially in view of the longer-term 
effectiveness. Assuming a positive effect of intensity 
of physiotherapy, this factor cannot counterbalance a 
possible positive effect of BoNT-A in our study: the 
mean intensity of physiotherapy was similar in the pe-
riod until primary end-point, and remained/was higher 
Fig. 1. Goal attainment scaling (GAS) for individual ”SMART” goals 
at the ICF activity level, unadjusted mean scores at baseline, 12 and 
24 weeks (SD). GAS scoring: –3 = deterioration; –2 = baseline score; 
–1 = improved but less than goal; 0 = goal attained; +1 = more than goal 
attained; +2 = far more than goal attained. SMART: specific, measurable, 
acceptable, relevant and time-related goals; BoNT-A: botulinum toxin; 
CR: comprehensive rehabilitation; SD: standard deviation.
-3 
-2 
-1 
0 
1 
2 BoNT-A+CR 
only-CR 
baseline  
(n=65) 
12 weeks  
(n=64) 
24 weeks 
(n=62) 
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logical responses to stretch can have multiple causes. 
Further investigations are therefore clearly warran-
ted, and the p-values presented in this paper should 
be interpreted with caution because of the disturbed 
randomization. In future research, instrumented/
quantitative assessment of different components of 
hyper-resistance should be applied (74). At the same 
time, it is important to focus on opening the black box, 
by defining the content of treatment in both interven-
tion and control groups, to enable us to better determine 
the best intervention for each patient (13, 75).
The main limitations of the current study were its 
pragmatically chosen partly-randomized design, the 
relatively small sample size, failed masking of out-
come assessor (37%) or physiotherapist (69%), and 
the lack of a control group without intervention. These 
have been discussed extensively previously (52). The 
potential bias related to differences in BoNT-A treat-
ment history between groups was not evident from 
the data. A strength of the current study is that, in 
contrast to most other studies, we included both legs 
in the comparative effectiveness analyses for children 
with bilateral spastic CP (instead of only the most in-
volved leg). This better reflects the true effectiveness 
of interventions for the bilaterally measured outcome 
measures. We agree with Ade-Hall that it is important 
to reflect clinical practice as closely as possible (3), and 
therefore only included legs in the analyses for an effect 
outcome when a BoNT-A-targeted muscle was expec-
ted to have an effect on that particular effect outcome 
according to a scheme based on expert opinion. This 
is debatable, of course, but in our opinion is the most 
valid way to evaluate the effectiveness of multi-level 
BoNT-A treatment. Underdosing was highly unlikely 
because the medical specialists applied the maximum 
recommended BoNT-A doses per large muscle group 
in relation to the age of the child.
In conclusion, at the group level, giving BoNT-A 
injections prior to rehabilitation did not increase the ef-
fectiveness of multimodal comprehensive rehabilitation 
treatment for ambulatory 4–12-year-old children with 
spastic CP. Since this applies to a wide range of effect 
outcomes across different ICF categories, it is now 
relevant to critically reconsider the indications for and 
use of BoNT-A treatment in this specific CP subgroup. 
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between primary end-point and follow-up in the group 
that received BoNT-A (700 min in this group vs 558 
min in the only-CR group, Table II). 
Since children have never been specifically excluded 
from regular standard care in the intervention groups in 
most, if not all, previous (randomized) controlled trials, 
conclusions regarding (especially long-term) BoNT-A 
effects have in fact been conclusions regarding the ef-
fects of BoNT-A plus (an)other co-intervention(s). This 
is especially the case in trials that focus on efficacy, 
safety and dosage of BoNT-A. However, efficacy and 
effectiveness research usually have different aims 
(73). The size of the contrast between intervention 
and comparator also differs, with generally larger 
contrasts in efficacy studies. Low-intensity “standard 
care” as comparative control intervention is, from a 
clinical effectiveness perspective, not the most logical 
choice, and may even be considered a priori inferior 
because they do not do justice to the current body of 
evidence for the non-pharmacological post-BoNT-A 
treatment packages for spastic CP. The comparative 
alternative intervention should be a full representative 
of best-available evidence for the non-pharmacological 
modalities that are applied in clinical practice to date. 
As we pointed out earlier (52), up to now, research 
questions and designs have been based on the implicit 
assumption that BoNT-A is the most active component 
in combined treatment packages. However, given the 
consensus that BoNT-A should never be a stand-alone 
treatment and an interdisciplinary multi-modal team 
approach is required (5), it may, in our opinion, be 
likely that physiotherapy was intensified after BoNT-A 
treatment in the intervention groups. This cannot be 
checked, however, because the post-BoNT-A interven-
tions and the interventions in the comparative interven-
tion largely remained ”black boxes” (35). It is difficult 
to weigh the current body of evidence, but based on 
our results, the assumption that BoNT-A creates better 
conditions to enhance the (long-term) effectiveness of 
adjunctive interventions may be questioned. It should 
be noted that, as long ago as 2000, Ade-Hall & Moore 
warned about premature acceptance of BoNT-A be-
cause of inconclusive evidence (3).
The current study does not question the working 
mechanism or efficacy of BoNT-A. This is related to 
the possibility of false indications for BoNT-A treat-
ment, even though the medical specialists involved in 
the current study had ample experience with BoNT-A. 
Clinical assessment of responses to passive muscle 
stretch is complicated, as it is difficult to distinguish 
reliably between non-neural (tissue-related) and neural 
(central nervous system related) contributions to hyper-
resistance (74). This clearly hampers the interpretation 
of findings because BoNT-A can only impact non-neural 
contributors to hyper-resistance, whereas pathophysio-
www.medicaljournals.se/jrm
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